Adjuvant Chemoimmunotherapy of Lung Adenocarcinoma
This clinical trial were enrolled 63 patients with lung adenocarcinoma after radical surgical resection of the tumor in thorax surgery branch of the Rostov-on-Don Scientific Research Institute of Oncology between of 2009 for 2011 year. 33 (52 %) patients received adjuvant chemoimmunotherapy with Ingaron, 30 (48 %) were assigned to receive conventional adjuvant chemotherapy. The median duration of follow-up was 22 months. Adjuvant chemoimmunotherapy improves the 3-year overall survival (18 %) and disease free survival (25 %) of radical operated patients with 1b–3a stages of lung adenocarcinoma compared with adjuvant chemotherapy.